VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation

November 27, 2024 01:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects.


Building on years of successful collaboration, Sartorius and the VectorBuilder have agreed to further expand the scope of their partnership. The new cooperation will cover various areas, such as co-development of innovative downstream processes for cell and gene therapies; further optimization of the development platform and commercial production of GMP-compliant mRNA, plasmid and viral vectors; partnering to support the achievement of sustainability goals; and regular exchange as well as training of talent from both companies. Moreover, VectorBuilder will be a developing partner for applications in the field of the new modalities.

"Sartorius is deeply committed to customer-centric innovation, which is the cornerstone of our product development and service provision," said Sarah Wang, Head of Sartorius China. "We anticipate that this strategic partnership will yield innovative solutions aimed at enhancing the efficiency and quality of biomedical enterprises. Together, we aim to support the growth of our global customers and the broader biomedical industry, and to contribute to the advancement of life sciences through transformative processes."

"Innovation is in the DNA of VectorBuilder. This agreement with Sartorius allows us to further expand our reach and impact, empowering researchers and pharmaceutical companies worldwide with advanced gene delivery solutions," said Dr. Bruce Lahn, Founder and Chief Scientist of VectorBuilder. "We are excited to combine our expertise to create a more efficient and effective biopharmaceutical ecosystem."

"By partnering with VectorBuilder, we look forward to leveraging the expertise of both companies to enable more innovations in downstream processing, further reducing time to market and ultimately saving more people's lives," Michaela Pischke added, Head of the Business Area Separation Technologies. "Congratulations to our China team who have done a great job in laying the groundwork to strengthen this partnership."

Both companies are committed to exploring the vast potential of cell and gene therapies and accelerating the translation of research breakthroughs into life-saving treatments.

About Sartorius
Sartorius | Biopharma, Laboratory, Applied & Life Sciences

About VectorBuilder
www.vectorbuilder.com


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.